Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Germany
Clinical trial register · Germany

Clinical Trials in Germany

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Essen 50 Berlin 45 Hamburg 28 Dresden 28 Cologne 28
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca188 Novartis Pharmaceuticals142 Hoffmann-La Roche99 Merck Sharp & Dohme LLC98 Eli Lilly and Company98 Charite University, Berlin, Germany95 Janssen Research & Development, LLC90 University Hospital Tuebingen87 AbbVie79 Universitätsklinikum Hamburg-Eppendorf78 Bristol-Myers Squibb67 Sanofi65 Boehringer Ingelheim61 Pfizer56 University Hospital Heidelberg52 Novo Nordisk A/S51 Amgen49 GlaxoSmithKline49 University of Erlangen-Nürnberg Medical School47 Technical University of Munich47 Heinrich-Heine University, Duesseldorf45 Technische Universität Dresden44 Bayer32 Takeda31 University of Ulm29 Show all 1399 Clear sponsor filter
Site location
Essen50 Berlin45 Hamburg28 Dresden28 Cologne28 Freiburg im Breisgau24 Leipzig21 Jena21 Munich20 Frankfurt am Main20 Mainz18 Würzburg17 Heidelberg17 Hanover16 Mannheim13 Ulm12 Münster12 München11 Aachen11 Erlangen11 Tübingen11 Bochum11 Halle9 Rostock8 Stuttgart8 Show all 117
All 117 locations
Target enrolment
to

Trials in this register

142 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
180
Stuttgart, Kaiserslautern, Berlin, Mannheim, Pirna
2026-09-18
Recruiting
Novartis Pharmaceuticals
Observational
470
Düren
2026-08-04
Recruiting
Novartis Pharmaceuticals
Phase 3
188
Wesel, Bielefeld
2026-08-04
Recruiting
Novartis Pharmaceuticals
Phase 2
100
Hamburg, Tübingen
2026-07-30
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Erlangen
2026-07-16
Recruiting
Novartis Pharmaceuticals
Phase 3
710
Freiburg im Breisgau, Würzburg, Darmstadt, Düsseldorf, Bochum, Minden
2026-07-10
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Munich, Würzburg, Bonn, Düsseldorf, Dresden, Leipzig, Beelitz, Berlin
2026-06-03
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
460
Mannheim, Jena, Aachen, Cottbus, Erlangen, Hamburg, Hanover, Minden
2026-05-27
Recruiting
Novartis Pharmaceuticals
Phase 1
208
Würzburg, Dresden
2026-05-25
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Mannheim, Muehldorf Am Inn, Munich, Weiden in Der Oberpfalz, Frankfurt am Main, Hanover, Cologne, Essen
2026-05-11
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Frankfurt am Main, Erlangen, Hamburg
2026-04-28
Recruiting
Novartis Pharmaceuticals
Observational
380
Baden-Baden, Heidenheim, Schwäbisch Hall, Winnenden, Aschaffenburg, Augsburg, Donauwörth, Herrsching am Ammersee
2026-04-17
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Munich, Hanover, Mainz
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Aachen, Bochum, Münster, Tübingen, Ulm
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Ludwigshafen, Bonn, Münster, Tübingen
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Munich, Bad Bentheim, Bielefeld, Hamburg, Hanover, Lübeck, Münster, Tübingen
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Jena, Essen
2026-01-13
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Jena, Essen
2025-12-29
Recruiting
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
DrugsAbiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
123
Dresden, Essen, München, Stuttgart
2025-12-05
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Munich, Potsdam, Frankfurt am Main, Kaiserslautern, Dresden, Bad Krozingen, Bad Oeynhausen, Berlin
2025-12-02
Recruiting
Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings
NCT07508007Implementing EAS/ESC Guideline Recommendation on Lp(a) Testing in Routine Practice
Novartis Pharmaceuticals
Observational
4,500
Nuremberg
2025-11-28
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
180
Essen
2025-11-24
Recruiting
Novartis Pharmaceuticals
Phase 1
112
Berlin
2025-11-20
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Freiburg im Breisgau, Mannheim, Munich, Unterhaching, Cottbus, Leipzig, Halle, Jena
2025-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Berlin, Hamburg, Mainz
2025-11-10
Recruiting
Novartis Pharmaceuticals
Phase 2
30
Sankt Augustin, Heidelberg, Münster
2025-11-03
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Bad Homburg, Berlin, Hamburg
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 3
12
Cologne, Berlin
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Düsseldorf, Jena
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Leipzig, Coburg, Erfurt, Essen, Hennigsdorf, Kiel
2025-10-03
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Berlin, München
2025-08-07
Active, closed
Novartis Pharmaceuticals
Phase 2
168
Düsseldorf, Hamburg, Lübeck, Nürtingen
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
Essen, Rostock
2025-07-03
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Marburg, Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster
2025-06-23
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Jena, Mainz
2025-06-12
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Erlangen, Essen, München
2025-05-30
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Dresden, Berlin, Mainz, Tübingen
2025-05-22
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Frankfurt am Main, Mainz, Bad Bentheim, Dresden, Hamburg, Heidelberg, Magdeburg, Münster
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Freiburg im Breisgau, Heidelberg, Ulm
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Recruiting
Novartis Pharmaceuticals
Phase 3
9
Frankfurt am Main
2025-02-28
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Bochum, Essen, Mainz, Ulm
2025-02-24
Recruiting
Novartis Pharmaceuticals
Observational
3,250
Baden-Baden, Filderstadt, Freudenstadt, Heidelberg, Heidenheim, Konstanz, Mannheim, Nürtingen
2025-02-20
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Frankfurt am Main, Gummersbach, Hamburg, Münster
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Langenau, Darmstadt, Dresden, Halle, Berlin, Bochum, Bonn, Erlangen
2025-01-31
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Essen, Mainz, Ulm
2024-12-12
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Freiburg im Breisgau, Frankfurt am Main, Hanover
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Munich, Bochum, Hamburg, Tübingen
2024-11-25
Active, closed
Novartis Pharmaceuticals
Phase 1
110
Cologne, Wuppertal, Aachen, Berlin, Essen, München, Rostock
2024-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Regensburg, Dresden, Berlin, Giessen, Greifswald, Heidelberg, Homburg
2024-10-24
Active, closed
Novartis Pharmaceuticals
Observational
519
Albstadt, Mannheim, Schwetzingen, Bamberg, Neuburg A.d. Donau, Regensburg, Unterhaching, Untermeitingen
2024-10-23
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Mannheim, Munich, Würzburg, Rostock, Berlin, Hanover, Lübeck, Münster
2024-10-17
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Cologne, Essen, München, Rostock
2024-10-15
Active, closed
Novartis Pharmaceuticals
Phase 2
203
Würzburg, Berlin
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 1
54
Berlin, Mainz
2024-10-08
Recruiting
Novartis Pharmaceuticals
Observational
500
Konstanz, Stuttgart, Munich, Regensburg, Würzburg, Cottbus, Frankfurt (Oder), Ludwigshafen
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
Erlangen, Essen, München, Tübingen
2024-08-14
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Kirchheim unter Teck, Munich, Ludwigshafen, Berlin, Mainz
2024-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Munich, Regensburg, Würzburg, Frankfurt am Main, Bochum, Essen
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 1
31
München, Rostock
2024-07-29
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Freiburg im Breisgau, Würzburg, Berlin, Herne
2024-06-28
Active, closed
Novartis Pharmaceuticals
Observational
116
Hamburg, Lingen, Koblenz, Leipzig, Halle, Ahaus, Berlin, Bremen
2024-06-11
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Cologne, Leipzig
2024-05-21
Active, closed
Novartis Pharmaceuticals
Phase 1
42
Essen, München
2024-05-15
Active, closed
Novartis Pharmaceuticals
Phase 2
23
Essen, München
2024-04-04
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Frankfurt am Main, Kaiserslautern, Dresden, Leipzig, Ahaus, Berlin, Bonn, Essen
2024-03-07
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Freiburg im Breisgau, Munich, Regensburg, Weiden in Der Oberpfalz, Langen, Bergisch Gladbach, Essen, Mönchengladbach
2024-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Essen, Kiel
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 2
49
Berlin
2024-01-03
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Göttingen, Stade, Dresden, Berlin, Mainz, Münster, Tübingen
2023-12-07
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
Freiburg im Breisgau, Mannheim, Cologne, Leipzig, Berlin, Ulm
2023-11-24
Active, closed
Novartis Pharmaceuticals
Phase 3
470
Freiburg im Breisgau, Munich, Hamburg, Göttingen, Stade, Dresden, Leipzig, Halle
2023-11-15
Active, closed
Novartis Pharmaceuticals
Phase 1
28
Cologne
2023-11-13
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover
2023-10-27
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Munich, Würzburg, Dresden, Jena, Berlin, Essen, Hamburg, Hanover
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Berlin, Bochum, Münster, Ulm
2023-08-25
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Dresden, Jena, Giessen
2023-08-16
Recruiting
Novartis Pharmaceuticals
Phase 4
700
Essen, München, Rostock
2023-08-14
Active, closed
Novartis Pharmaceuticals
Observational
436
Freiburg im Breisgau, Rheinstetten, Haßfurt, Kulmbach, Lauf an der Pegnitz, Nuremberg, Panketal, Hamburg
2023-08-10
Active, closed
Novartis Pharmaceuticals
Phase 3
100
Frankfurt am Main, Berlin, Tübingen
2023-07-11
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Augsburg, Hanover, Mainz, Trier, Magdeburg, Jena, Essen
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Essen
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Dresden, Leipzig, Lübeck
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Freiburg im Breisgau, Cologne, Leipzig, Herne, Mainz
2023-04-21
Active, closed
Novartis Pharmaceuticals
Phase 4
240
Bad Doberan, Berlin, Hamburg, Herne, Ratingen
2023-03-28
Active, closed
Novartis Pharmaceuticals
Phase 2
33
Freiburg im Breisgau
2023-02-28
Recruiting
Novartis Pharmaceuticals
Phase 3
195
Frankfurt am Main, Freiburg im Breisgau
2023-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Frankfurt am Main, Dresden, Jena
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Cologne, Dresden, Jena
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Dresden, Essen, Giessen, Hanover
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Munich, Marburg, Bramsche, Göttingen, Merzig, Dresden, Leipzig, Halle
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
95
Kempten (Allgäu), Halle, Hamburg, Oldenburg, Tübingen
2022-12-06
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Freiburg im Breisgau, Mannheim, Munich, Würzburg, Frankfurt am Main, Marburg, Paderborn, Velbert
2022-11-21
Active, closed
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
DrugsKeytruda·Pembrolizumab
Novartis Pharmaceuticals
Phase 1
126
Dresden, Essen
2022-10-26
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Frankfurt am Main, Jena, Berlin, Kiel
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Cologne, Dresden, Berlin, Hanover, Herne
2022-08-04
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Aachen, Bochum
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 1/2
55
Essen
2022-07-13
Active, closed
Novartis Pharmaceuticals
Phase 1/2
66
Essen, Heidelberg
2022-07-04
Recruiting
Novartis Pharmaceuticals
Observational
800
Albstadt, Hettingen, Mannheim, Nagold, Schwäbisch Hall, Schwetzingen, Bamberg, Dillingen an der Donau
2022-05-10
Active, closed
Novartis Pharmaceuticals
Phase 1/2
46
Erlangen, Essen, Hamburg
2021-12-27
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Cologne, Augsburg, Berlin, Essen, Lübeck
2021-12-17
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Freiburg im Breisgau, Essen, Hamburg
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 1
137
Essen
2021-10-21
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Mannheim, Frankfurt am Main, Jena, Aachen, Berlin, Lübeck
2021-10-06
Active, closed
Novartis Pharmaceuticals
Phase 3
129
Freiburg im Breisgau, Göttingen, Bochum
2021-10-05
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Freiburg im Breisgau, Stuttgart, Aachen, Berlin, Essen, Hanover, Heidelberg, Kiel
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Cologne, Aachen, Erlangen, Essen, Hamburg, Hanover, Heidelberg, Mainz
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Dresden, Aachen, Essen, Hamburg, Riesa, Ulm
2021-07-27
Recruiting
Novartis Pharmaceuticals
Phase 4
130
Heidelberg
2021-06-10
Active, closed
Novartis Pharmaceuticals
Phase 3
1,144
Würzburg, Cologne, Essen, München, Münster, Rostock
2021-06-09
Active, closed
Novartis Pharmaceuticals
Phase 2
236
Freiburg im Breisgau, Düsseldorf, Leipzig, Hamburg, Heidelberg
2021-04-19
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ulm, Augsburg, Halle, Jena, Hamburg
2021-04-09
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Freiburg im Breisgau, Cologne, Dresden, Essen
2021-02-24
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Berlin
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Cloppenburg, Hanover, Hoyerswerda, Jena, Villingen-Schwenningen, Würzburg
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 2
134
Dresden, Essen, Heidelberg, Tübingen
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Cologne, Augsburg, Berlin, Essen, Hamburg
2019-11-04
Active, closed
Novartis Pharmaceuticals
Phase 1
120
Jena, Essen, Heidelberg, Ulm
2019-10-30
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Erlangen, Essen, Hamburg, Heidelberg, Mainz
2019-10-03
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Stuttgart, Cologne, Berlin, Essen
2019-07-26
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
DrugIbrutinib
Novartis Pharmaceuticals
Phase 1/2
218
Frankfurt am Main, Leipzig
2019-06-26
Active, closed
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
NCT03891953Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
98
Dresden, Essen
2019-05-07
Active, closed
Novartis Pharmaceuticals
Phase 2
22
Berlin, Essen
2019-03-13
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Munich, Neuburg A.d. Donau, Unterhaching, Marburg, Cologne, Dresden, Leipzig, Barsinghausen
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Ravensburg, Munich, Würzburg, Cottbus, Frankfurt am Main, Georgsmarienhütte, Hanover, Essen
2018-12-07
Active, closed
Novartis Pharmaceuticals
Phase 1
105
Cologne, Essen
2018-01-29
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Mannheim, Augsburg, Berlin, Essen, Hamburg, Heidelberg
2018-01-26
Active, closed
Novartis Pharmaceuticals
Phase 2
29
Cologne, Hanover
2017-07-04
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Cologne
2016-12-15
Active, closed
Novartis Pharmaceuticals
Phase 4
233
Regensburg, Cologne, Essen, Heidelberg, Würzburg
2015-12-11
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Munich, Regensburg, Würzburg, Frankfurt am Main, Cologne, Leipzig, Berlin, Hamburg
2015-11-02
Active, closed
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
NCT02381886Advanced Malignancies That Harbor IDHR132 Mutations
Novartis Pharmaceuticals
Phase 1
166
Cologne, Jena, Heidelberg
2015-03-06
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsPanobinostat·Jakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Dresden, Jena, Aachen, Hamburg, Magdeburg, Mainz, Ulm
2015-03-05
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Freiburg im Breisgau, Göttingen, Dresden, Bochum, Erlangen
2013-07-26
Rows per page Showing 1–142 of 142
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-germany

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 142 of those studies that match the filters currently applied.

How many clinical trials are recruiting in Germany?

56 of the 142 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 86 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 142 studies
PhaseStudiesRecruitingShare
Phase 3552238.7%
Phase 2341223.9%
Phase 118412.7%
Phase 1/215610.6%
Phase 41057%
Observational966.3%
Phase 2/3110.7%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals14256

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Chronic Spontaneous Urticaria (5) Relapsing Multiple Sclerosis (5) Hidradenitis Suppurativa (4) Multiple Sclerosis (3) Breast Cancer (3) Carcinoma, Non-Small-Cell Lung (3) Melanoma (3) Early Breast Cancer (2) Advanced HR+/HER2- Breast Cancer (2) Advanced CCNE1-amplified Solid Tumors (2) Systemic Lupus Erythematosus (2) Chronic Myelogenous Leukemia (2) Primary Immune Thrombocytopenia (ITP) (2) PIK3CA-related Overgrowth Spectrum (PROS) (2) IgA Nephropathy (2)
→

Browse trials by site location

Essen (50) Berlin (45) Hamburg (28) Dresden (28) Cologne (28) Freiburg im Breisgau (24) Leipzig (21) Jena (21) Munich (20) Frankfurt am Main (20) Mainz (18) Würzburg (17) Heidelberg (17) Hanover (16) Mannheim (13)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.